Navigation Links
Sinovac Releases Statement on Healive Vaccine Suspension
Date:12/2/2008

BEIJING, Dec. 2 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Alternext US: SVA), a leading provider of vaccines in China, announced today that, the Health Services Bureau of Fengtai District in the City of Beijing suspended the use of 83 doses of inactivated hepatitis A vaccine Healive(R), following a report of the death of a minor in the Fengtai District on November 27, 2008, which coincided with the administration of the vaccine two days prior.

The suspended vaccine was part of lot 2008052105 that passed the routine government inspection in July 2008. To date, 19,850 doses vaccines from the lot have been distributed. According to data released by the Center for Adverse Drug Reaction Monitoring of Beijing, there is no other reported adverse reaction to the lot to date. Sinovac has not received, and is not aware of, similar notice of suspension from any other district in Beijing where the lot has been distributed or any other part of China where other lots of the Healive(R) vaccine have been distributed. On November 29, 2008, the Beijing Drug Administration and Drug Administration of Haidian District of City of Beijing conducted a joint administrative investigation that included an inspection of the company's manufacturing site and review of its manufacturing, inspection and sales processes, and concluded in a written report that no abnormality was found.

Sinovac has full confidence in the quality of its products. It will continue to cooperate with government agencies in their investigation of the incident and will provide an update once the investigation is completed.

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's commercialized vaccines include Healive(R) (hepatitis A), Bilive(R) (combined hepatitis A and B), Anflu(R) (influenza) and Panflu(TM) (H5N1). Sinovac is currently developing Universal Pandemic Influenza vaccine and Japanese encephalitis vaccine. Additional information about Sinovac is available on its website, http://www.sinovac.com . To be added to our distribution list, please email: info@sinovac.com.

    For more information, please contact:

     Helen G. Yang
     Sinovac Biotech Ltd.
     Tel:   +86-10-8289-0088 x871
     Fax:   +86-10-6296-6910
     Email: info@sinovac.com

    Investors/Media:
     Stephanie Carrington / Janine McCargo
     The Ruth Group
     Tel:   +1-646-536-7017/7033
     Email: scarrington@theruthgroup.com / jmccargo@theruthgroup.com

'/>"/>
SOURCE Sinovac Biotech Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Sinovac Reports Third Quarter 2008 Unaudited Financial Results
2. Sinovac Named to Deloitte Technology Fast 50 China
3. Sinovac to Participate in Two Upcoming Investor Conferences
4. Sinovacs Credit Rating Upgraded to AAZ, Second Highest Rating
5. Sinovac Biotech Holds 2007 Annual General Meeting
6. Sinovac to Present at the 2008 UBS Global Life Sciences Conference
7. Sinovac Initiates Clinical Trials for Inactivated Hepatitis A Vaccine in Ukraine
8. Sinovac Launches Seasonal Influenza Vaccine Anflu(R) for 2008-2009 Flu Season
9. Sinovac Adjourns Annual General Meeting
10. Sinovac to Present at the Susquehanna Financial Groups Second Annual Beijing Management Summit Conference
11. Sinovac Reports Record Second Quarter 2008 Unaudited Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... , ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical ... mesothelioma. Their findings are the subject of a new article on the Surviving Mesothelioma ... in the blood, lung fluid or tissue of mesothelioma patients that can help point ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... is pleased to announce the launch of their brand, UP4™ Probiotics, into Target ... over 35 years, is proud to add Target to its list of well-respected ...
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
(Date:6/23/2016)... , June 23, 2016 Houston ... with the Cy-Fair Sports Association to serve as ... the agreement, Houston Methodist Willowbrook will provide sponsorship ... and connectivity with association coaches, volunteers, athletes and ... with the Cy-Fair Sports Association and to bring ...
Breaking Biology Technology:
(Date:6/16/2016)... June 16, 2016 The ... expected to reach USD 1.83 billion by 2024, ... Research, Inc. Technological proliferation and increasing demand in ... expected to drive the market growth. ... The development of advanced multimodal techniques for ...
(Date:6/3/2016)... 2016 Das DOTM ... Nepal hat ein 44 Millionen ... Kennzeichen, einschließlich Personalisierung, Registrierung und IT-Infrastruktur, an ... und Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte internationale ... teilgenommen, aber Decatur wurde als konformste und ...
(Date:5/24/2016)... facilitates superior patient care by providing unparalleled technology to leaders of the medical imaging ... product recently added to the range of products distributed by Ampronix. Photo ... ... ... News ...
Breaking Biology News(10 mins):